DK1961767T3 - Diagnose og behandling af cancere og andre lidelser - Google Patents

Diagnose og behandling af cancere og andre lidelser

Info

Publication number
DK1961767T3
DK1961767T3 DK08156593.9T DK08156593T DK1961767T3 DK 1961767 T3 DK1961767 T3 DK 1961767T3 DK 08156593 T DK08156593 T DK 08156593T DK 1961767 T3 DK1961767 T3 DK 1961767T3
Authority
DK
Denmark
Prior art keywords
cancers
disorders
diagnosis
treatment
proline
Prior art date
Application number
DK08156593.9T
Other languages
English (en)
Inventor
Angus Gidley-Baird
Julian Alexander Barden
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR2579A external-priority patent/AUPR257901A0/en
Priority claimed from AUPR5890A external-priority patent/AUPR589001A0/en
Priority claimed from AUPR5891A external-priority patent/AUPR589101A0/en
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Application granted granted Critical
Publication of DK1961767T3 publication Critical patent/DK1961767T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
DK08156593.9T 2001-01-17 2002-01-17 Diagnose og behandling af cancere og andre lidelser DK1961767T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AUPR2579A AUPR257901A0 (en) 2001-01-17 2001-01-17 Diagnosis and treatment of malignant lymphoma
AUPR025701 2001-01-17
AUPR5890A AUPR589001A0 (en) 2001-06-22 2001-06-22 An antibody cancer therapeutic
AUPR5891A AUPR589101A0 (en) 2001-06-22 2001-06-22 Diagnosis of cell cancers using an antibody to non-functionalP2X, receptors
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
EP02715313A EP1360203B1 (en) 2001-01-17 2002-01-17 Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions

Publications (1)

Publication Number Publication Date
DK1961767T3 true DK1961767T3 (da) 2012-05-29

Family

ID=27507500

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02715313T DK1360203T3 (da) 2001-01-17 2002-01-17 Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
DK08156593.9T DK1961767T3 (da) 2001-01-17 2002-01-17 Diagnose og behandling af cancere og andre lidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02715313T DK1360203T3 (da) 2001-01-17 2002-01-17 Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande

Country Status (15)

Country Link
US (10) US7326415B2 (da)
EP (2) EP1360203B1 (da)
JP (2) JP4384852B2 (da)
CN (2) CN100497385C (da)
AT (2) ATE418565T1 (da)
AU (1) AU2003235005B2 (da)
CA (1) CA2434490C (da)
DE (1) DE60230482D1 (da)
DK (2) DK1360203T3 (da)
ES (2) ES2320421T3 (da)
HK (3) HK1070903A1 (da)
MY (1) MY158262A (da)
PT (1) PT1360203E (da)
TW (1) TWI319011B (da)
WO (1) WO2002057306A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CA2434490C (en) 2001-01-17 2014-06-03 Intreat Pty Limited Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
CN100497386C (zh) * 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
JP4413617B2 (ja) * 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
GB0229139D0 (en) * 2002-12-13 2003-01-15 Glaxo Group Ltd Gene polymorphisms
WO2007146061A2 (en) * 2006-06-09 2007-12-21 University Hospitals Of Cleveland Cell collection and disease screening
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
EP2082032A4 (en) 2006-10-10 2010-06-30 Biosceptre Int Ltd ANTIBODIES AGAINST NON-FUNCTIONAL P2X7 RECEPTOR PRODUCING HYBRIDOMES
EP2201026B1 (en) * 2007-09-14 2017-01-04 Biosceptre (Aust) Pty Ltd Novel p2x7 epitopes
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
US8293491B2 (en) 2007-09-14 2012-10-23 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
KR101701300B1 (ko) 2008-07-04 2017-02-01 바이오셉터 (어스트) 피티와이 엘티디 항­ｐ２ｘ７ 펩티드 및 에피토프
CN102257003B (zh) * 2008-12-19 2017-04-05 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
JP5936067B2 (ja) 2009-08-20 2016-06-15 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 抗ｐ２ｘ７受容体抗体およびその断片
US8771693B2 (en) * 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
ES2667003T3 (es) 2009-12-24 2018-05-09 Biosceptre (Aust) Pty Ltd Anticuerpos para receptores P2X7 oligoméricos no funcionales
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
WO2012149334A2 (en) * 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
BR112013033974A2 (pt) 2011-07-01 2017-02-14 Biosceptre Int Ltd terapia de combinação
US11260131B2 (en) 2016-10-21 2022-03-01 Biosceptre (Aust) Pty Ltd Cytotoxic particles for targeting P2X7 receptor
CN117903140A (zh) 2018-02-27 2024-04-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
TWI829716B (zh) 2018-07-05 2024-01-21 美商英塞特公司 作為a2a/a2b 抑制劑之稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
MX2023007850A (es) 2020-12-29 2023-09-11 Incyte Corp Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).
WO2024055077A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd Enrichment of engineered immune cells
WO2024055075A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells
WO2024055076A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd Methods of detecting immune cells

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1141314A (en) * 1914-12-19 1915-06-01 Eugene W Caldwell Photographic developing apparatus.
US2191508A (en) * 1939-02-06 1940-02-27 Stuart Robert Photographic film carrier and development receptacle
US3010460A (en) * 1958-07-03 1961-11-28 Geo B Hart Inc Apparatus for wetting absorbent bodies for moistening and supporting plant parts
US3077155A (en) * 1960-08-08 1963-02-12 Pako Corp Device for treating photographic sheet material
US3121438A (en) * 1961-01-16 1964-02-18 Union Carbide Corp Open head container and cover therefor
US3952756A (en) * 1974-06-14 1976-04-27 Purex Corporation Semi automatic parts cleaning machine
US4302273A (en) * 1980-06-04 1981-11-24 Rca Corporation Etching tank in which the solution circulates by convection
US4305413A (en) * 1980-07-25 1981-12-15 Ecology, Inc. Cleaning apparatus
US4550579A (en) * 1984-04-13 1985-11-05 Frank Clifford G Apparatus for the dyeing of shaped articles
US5104727A (en) * 1989-06-16 1992-04-14 W. L. Gore & Associates, Inc. Air bag laminates
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
JPH0756015A (ja) * 1993-08-18 1995-03-03 Sony Corp カラーフィルタの製造方法
JPH10501122A (ja) 1994-05-27 1998-02-03 グラクソ、グループ、リミテッド Ｐ▲下２ｘ▼レセプター（プリノセプターファミリー）
US5660640A (en) * 1995-06-16 1997-08-26 Joray Corporation Method of removing sputter deposition from components of vacuum deposition equipment
CA2228999A1 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
EP0907729A1 (en) 1996-04-30 1999-04-14 Smithkline Beecham Plc HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US5851307A (en) * 1997-04-28 1998-12-22 Advanced Micro Devices, Inc. Method for in-situ cleaning of polysilicon-coated quartz furnaces
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US5849091A (en) * 1997-06-02 1998-12-15 Micron Technology, Inc. Megasonic cleaning methods and apparatus
US5906216A (en) * 1997-10-10 1999-05-25 Barlet; Bruce N. Denture cleaning device
ES2629442T3 (es) 1998-06-01 2017-08-09 Agensys, Inc. Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6055694A (en) * 1998-11-30 2000-05-02 Tsk America, Inc. Wafer scrubbing machine
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
WO2001030964A2 (en) 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CA2434490C (en) 2001-01-17 2014-06-03 Intreat Pty Limited Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
CN100497386C (zh) 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
ATE371738T1 (de) 2003-04-17 2007-09-15 Affectis Pharmaceuticals Ag Mittel und verfahren zur diagnose und behandlung affektiver störungen
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100036101A1 (en) 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
EP2082032A4 (en) 2006-10-10 2010-06-30 Biosceptre Int Ltd ANTIBODIES AGAINST NON-FUNCTIONAL P2X7 RECEPTOR PRODUCING HYBRIDOMES
EP2201026B1 (en) 2007-09-14 2017-01-04 Biosceptre (Aust) Pty Ltd Novel p2x7 epitopes
US8293491B2 (en) 2007-09-14 2012-10-23 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
KR101701300B1 (ko) 2008-07-04 2017-02-01 바이오셉터 (어스트) 피티와이 엘티디 항­ｐ２ｘ７ 펩티드 및 에피토프
JP5936067B2 (ja) 2009-08-20 2016-06-15 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 抗ｐ２ｘ７受容体抗体およびその断片
ES2667003T3 (es) 2009-12-24 2018-05-09 Biosceptre (Aust) Pty Ltd Anticuerpos para receptores P2X7 oligoméricos no funcionales
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
BR112013033974A2 (pt) 2011-07-01 2017-02-14 Biosceptre Int Ltd terapia de combinação

Also Published As

Publication number Publication date
ES2383712T3 (es) 2012-06-25
US20040142342A1 (en) 2004-07-22
US20110092674A1 (en) 2011-04-21
US20150274839A1 (en) 2015-10-01
TWI319011B (en) 2010-01-01
US20170327592A1 (en) 2017-11-16
EP1961767A2 (en) 2008-08-27
DE60230482D1 (de) 2009-02-05
JP4457169B2 (ja) 2010-04-28
US20080131438A1 (en) 2008-06-05
US20130245226A1 (en) 2013-09-19
US10450380B2 (en) 2019-10-22
ATE418565T1 (de) 2009-01-15
US8399617B2 (en) 2013-03-19
US7888473B2 (en) 2011-02-15
WO2002057306A1 (en) 2002-07-25
ES2320421T3 (es) 2009-05-22
US20140323693A1 (en) 2014-10-30
MY158262A (en) 2016-09-30
US9663584B2 (en) 2017-05-30
JP2004528286A (ja) 2004-09-16
EP1961767B1 (en) 2012-03-07
EP1360203B1 (en) 2008-12-24
EP1360203A1 (en) 2003-11-12
US7531171B2 (en) 2009-05-12
CN101555283B (zh) 2012-03-21
US20090192293A1 (en) 2009-07-30
DK1360203T3 (da) 2009-04-20
US7326415B2 (en) 2008-02-05
US8080635B2 (en) 2011-12-20
ATE548383T1 (de) 2012-03-15
JP4384852B2 (ja) 2009-12-16
JP2009235074A (ja) 2009-10-15
CA2434490C (en) 2014-06-03
HK1070903A1 (en) 2005-06-30
CN101555283A (zh) 2009-10-14
US20120059151A1 (en) 2012-03-08
CN100497385C (zh) 2009-06-10
US20200071419A1 (en) 2020-03-05
PT1360203E (pt) 2009-04-03
EP1360203A4 (en) 2005-06-22
EP1961767A3 (en) 2008-10-29
HK1123311A1 (en) 2009-06-12
AU2003235005B2 (en) 2007-09-20
CA2434490A1 (en) 2002-07-25
AU2003235005A1 (en) 2003-09-11
AU2003235005A8 (en) 2003-09-11
CN1541222A (zh) 2004-10-27
US8709425B2 (en) 2014-04-29
HK1138013A1 (en) 2010-08-13

Similar Documents

Publication Publication Date Title
DK1961767T3 (da) Diagnose og behandling af cancere og andre lidelser
TR200401871T4 (tr) Değiştirilen oktanoil amitlerin (octanoyl amides) hazırlanması
DE60137876D1 (de) Analoge des Glucagon-ähnlichen Peptids-1
ITUD20030092A1 (it) Protesi per l'articolazione della spalla.
HUP0101719A2 (hu) Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával
EP1357909A4 (en) ANTAGONISTS OF IL-8 RECEPTORS
EA200400399A1 (ru) Способы лечения легочных заболеваний
DE60211810D1 (de) Pyrolyserohr und dieses verwendendes pyrolyseverfahren
DE60325377D1 (de) Motilidverbindungen
DE60112671D1 (de) Gebogener, elastischer Zahnregulierungsring
ITTO20000674A0 (it) Composizioni a base di aminoacidi, atte al trattamento dell'insufficienza cardiaca.
NO20000731D0 (no) Neisseria-lactodweeinbindingsprotein
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
ATE373718T1 (de) 17867, eine menschliche aminopeptidase
BR0212295A (pt) Ensaio
DK1122307T3 (da) Human carnosinase 2
MXPA04004980A (es) Antagonistas del receptor ccr-3.
GB2368524B (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
DK1395289T3 (da) Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist
MXPA03008136A (es) Proyector epidiascopico que tiene poste plegable.
Manukhin On using the power cross section of elastic interaction; K voprosu ob ispol'zovanii stepennogo secheniya uprugogo vzaimodejstviya
FR2829382B1 (fr) Table d'etirement cybernetique du rachis
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
DE69104363T2 (de) Vinylsulfonyl pristinamycine und deren herstellung.